StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN – Free Report) in a report published on Saturday. The brokerage issued a sell rating on the medical research company’s stock.
OpGen Stock Down 12.5 %
NASDAQ OPGN opened at $1.40 on Friday. OpGen has a 52 week low of $1.40 and a 52 week high of $9.90. The stock’s 50-day moving average price is $1.86 and its 200-day moving average price is $2.58.
OpGen (NASDAQ:OPGN – Get Free Report) last released its earnings results on Monday, August 19th. The medical research company reported ($1.18) EPS for the quarter. The business had revenue of $0.03 million for the quarter.
About OpGen
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
Recommended Stories
- Five stocks we like better than OpGen
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- How to Evaluate a Stock Before BuyingÂ
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- Dividend Capture Strategy: What You Need to Know
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.
